Literature DB >> 21905976

YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis.

Timo Rath1, Martin Roderfeld, Can Güler, Christian Wenzel, Jürgen Graf, Frigga Beitinger, Elke Roeb, Reinhart Zachoval.   

Abstract

OBJECTIVE: Transient elastography (TE) is a non-invasive and accurate method for the diagnosis of severe hepatic fibrosis and cirrhosis (F = 3 and F = 4). However, the assessment of significant fibrosis (F = 2) by TE is impaired due to a high variation in the diagnostic accuracy. Within this study, we aim to compare the diagnostic value of TE and experimental biomarkers of liver fibrosis.
MATERIAL AND METHODS: A total of 55 patients with chronic liver disease of different etiologies were included in the study. Among them, patients with HCV infection represented the largest cohort (n = 25). Liver fibrosis was evaluated according to the Desmet/Scheuer score. All patients received TE. Serum concentrations of YKL-40, hyaluronic acid (HA), Laminin, C-terminal procollagen I peptide, MMP-9, TIMP-1, TIMP-2 and MMP-9/TIMP-1 complex were determined by ELISA.
RESULTS: In the total patient population, areas under the receiver operator characteristic curve (AUROC) for TE were 0.798 (F ≥ 2), 0.880 (F ≥ 3) and 1 (F = 4). Among the serum markers, highest diagnostic accuracies were calculated for YKL-40 for F ≥ 2 (0.792) and F ≥ 3 (0.914) and for YKL-40 and HA for F = 4 (both 0.936). In the subgroup of HCV patients, the following AUROCs for TE were calculated: 0.802 (F ≥ 2), 0.798 (F ≥ 3) and 0.998 (F = 4). YKL-40 exhibited the highest diagnostic accuracy of all biomarkers in the HCV population (0.880, 0.854 and 0.986, respectively).
CONCLUSIONS: YKL-40 is a powerful fibrosis marker with high diagnostic accuracy, in particular in HCV-associated liver disease. Its determination may confirm and improve the diagnostic accuracy of TE especially in early stages of liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21905976     DOI: 10.3109/00365521.2011.613949

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

Review 1.  The significance of YKL-40 protein in liver fibrosis.

Authors:  Hui Tao; Jing-Jing Yang; Kai-Hu Shi; Cheng Huang; Lei Zhang; Xiong-Wen Lv; Jun Li
Journal:  Inflamm Res       Date:  2014-01-19       Impact factor: 4.575

Review 2.  Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease.

Authors:  Chavdar S Pavlov; Giovanni Casazza; Dimitrinka Nikolova; Emmanuel Tsochatzis; Andrew K Burroughs; Vladimir T Ivashkin; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2015-01-22

3.  CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis.

Authors:  Haijun Huang; Tiangang Wu; Jian Mao; Yongxing Fang; Jiajie Zhang; Lihua Wu; Shu Zheng; Biaoyang Lin; Hongying Pan
Journal:  OMICS       Date:  2015-06

4.  Diagnostic Value of Serum Chitinase-3-Like Protein 1 for Liver Fibrosis: A Meta-analysis.

Authors:  Xiaoting Huang; Jialing Zhuang; Yongqiang Yang; Jiaxin Jian; Wen Ai; Chunyong Liu; Wenzhi Tang; Changyu Jiang; Yongshen He; Lesheng Huang; Se Peng
Journal:  Biomed Res Int       Date:  2022-03-20       Impact factor: 3.411

5.  Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease.

Authors:  Timo Rath; Lisa Hage; Marion Kügler; Katrin Menendez Menendez; Reinhart Zachoval; Lutz Naehrlich; Richard Schulz; Martin Roderfeld; Elke Roeb
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

6.  Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors.

Authors:  Edana Cassol; Vikas Misra; Alexander Holman; Anupa Kamat; Susan Morgello; Dana Gabuzda
Journal:  BMC Infect Dis       Date:  2013-05-04       Impact factor: 3.090

7.  Serum YKL-40 levels and chitotriosidase activity in patients with beta-thalassemia major.

Authors:  Maria Musumeci; Vincenzo Caruso; Emilia Medulla; Venerando Torrisi; Roberta Migale; Silvia Angeletti; Salvatore Musumeci
Journal:  Dis Markers       Date:  2014-04-08       Impact factor: 3.434

8.  Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease.

Authors:  Dennis B Holmgaard; Lone H Mygind; Ingrid L Titlestad; Hanne Madsen; Svend Stenvang Pedersen; Julia S Johansen; Court Pedersen
Journal:  BMC Pulm Med       Date:  2013-12-30       Impact factor: 3.317

9.  Serum Markers of Epithelial Mesenchymal Transition as Predictors of HCV-induced Liver Fibrosis, Cirrhosis and Hepatocellular Carcinoma.

Authors:  Mona M Zoheiry; Shaimaa Aa Hasan; Eman El-Ahwany; Faten M Nagy; Hoda Abu Taleb; Mona Nosseir; Mona Magdy; Safa Meshaal; Mohamed Darwish El-Talkawy; Inas Raafat
Journal:  Electron Physician       Date:  2015-12-20

10.  Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication.

Authors:  Qian Kang; Jianhong Chen; Hao Luo; Ning Tan; Hui Gao; Xiaxia Zhang; Min Yu; Dan Liu; Hongli Xi; Yaoyu An; Yifan Han; Ran Cheng; Xiaoyuan Xu
Journal:  Dis Markers       Date:  2020-10-01       Impact factor: 3.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.